Opportunity Information: Apply for PAR 13 320
Apply for PAR 13 320
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Multicenter Osteoarthritis Study (MOST) (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Sep 11, 2013 and posted on Aug 6, 2013.
- Applicants must submit their applications by Sep 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
PAR-13-320, titled "Limited Competition Multicenter Osteoarthritis Study (MOST) (U01)," is a National Institutes of Health (NIH) discretionary funding opportunity using the cooperative agreement mechanism (U01). It is a limited competition renewal announcement designed specifically to enable the existing MOST investigator team to apply for continued support for an additional five-year project period. The FOA also explicitly allows for resubmission and potential future revision applications, reflecting NIH's intent to maintain continuity for a long-running, high-value longitudinal cohort rather than open the competition broadly to new cohorts or new coordinating teams.
The scientific focus of the opportunity is knee osteoarthritis (OA), with an emphasis on understanding how the disease develops and progresses over time, particularly in relation to biomechanical factors and structural abnormalities. MOST is described as the first large-scale observational knee OA study to prospectively examine these relationships, which is important because prospective, repeated-measures cohort data are crucial for teasing apart temporal relationships between risk factors, imaging changes, symptoms, and functional decline. The cohort is considered uniquely valuable because it includes individuals who either already had knee OA at baseline or were at elevated risk due to one or more recognized risk factors, allowing analyses across a spectrum from pre-disease risk to established disease and progression.
A major strength highlighted in the FOA is the depth and duration of existing data already collected. The study includes more than seven years of repeated clinical and musculoskeletal evaluations in 3,026 participants who were between 50 and 79 years old at enrollment. Data resources include repeated knee radiographs and knee MRI imaging, along with strength testing and physical performance measures, enabling both structural (imaging-based) and functional (performance-based) assessments of OA. In addition, the cohort includes plasma samples and has established a specimen bank intended to support future biochemical and genetic investigations, including the study of biomarkers relevant to OA risk, onset, and progression. This combination of longitudinal imaging, clinical measures, functional testing, and biospecimens supports a wide range of research questions, including validation of imaging markers, identification of predictors of progression, and exploration of biological pathways through biomarker and genetic analyses.
From an administrative standpoint, the FOA falls under the NIH health-related activity category and is indexed to CFDA number 93.866 (Aging Research). It does not require cost sharing or matching. The opportunity was posted August 6, 2013, with an original and current closing date of September 7, 2017, and it was archived October 8, 2017. While the eligibility section lists a broad set of applicant organization types commonly seen in NIH announcements (including public and private institutions of higher education and various nonprofit categories, as well as specific designations such as HBCUs, HSIs, TCCUs, and other serving institutions), the key practical point is that this is a limited competition intended for the MOST investigators to submit the renewal, so eligibility is effectively constrained by that purpose. Non-U.S. (foreign) institutions are not eligible to apply as applicant organizations, though non-domestic components of U.S. organizations are eligible, and foreign components (as defined by NIH policy) are allowed.
Overall, the grant opportunity is best understood as a continuation mechanism to preserve and extend one of the most comprehensive U.S. observational resources for knee OA. NIH is using the U01 cooperative agreement format to support a structured partnership with investigators to sustain follow-up, continue rigorous repeated assessments, and maximize the scientific yield of an established cohort and specimen bank that can inform prevention strategies, prognostic tools, and biomarker discovery for osteoarthritis.
FAQs: PAR-13-320 Limited Competition Multicenter Osteoarthritis Study (MOST) (U01)
What is PAR-13-320?
PAR-13-320 is a National Institutes of Health (NIH) discretionary funding opportunity announcement titled "Limited Competition Multicenter Osteoarthritis Study (MOST) (U01)." It supports continued work on the Multicenter Osteoarthritis Study (MOST) using the U01 cooperative agreement mechanism.
What type of funding mechanism is used?
This opportunity uses a cooperative agreement (U01). It is described as a structured partnership mechanism where NIH and the investigators work cooperatively.
Is this an open competition for new research teams or new cohorts?
No. This is a limited competition renewal announcement designed specifically to enable the existing MOST investigator team to apply for continued support. The intent is to maintain continuity for a long-running longitudinal cohort rather than open the competition broadly to new cohorts or new coordinating teams.
What is the purpose of this limited competition renewal?
The main purpose is to preserve and extend one of the most comprehensive U.S. observational resources for knee osteoarthritis by continuing follow-up and repeated assessments, and by maximizing the scientific yield of an established cohort and specimen bank.
What is the project period supported by this renewal?
The renewal is intended to provide continued support for an additional five-year project period.
Does the FOA allow resubmissions or future revisions?
Yes. The FOA explicitly allows for resubmission and indicates potential future revision applications, reflecting NIH's intent to support continuity of the MOST cohort resource.
What scientific topic does the opportunity focus on?
The scientific focus is knee osteoarthritis (OA), with emphasis on understanding how the disease develops and progresses over time, particularly in relation to biomechanical factors and structural abnormalities.
Why is a prospective longitudinal cohort important for this research?
Prospective, repeated-measures cohort data are described as crucial for evaluating temporal relationships among risk factors, imaging changes, symptoms, and functional decline. The MOST study is highlighted as a large-scale observational knee OA study designed to prospectively examine these relationships.
Who is included in the MOST cohort described in the announcement?
The cohort includes 3,026 participants who were between 50 and 79 years old at enrollment. Participants either already had knee OA at baseline or were at elevated risk due to one or more recognized risk factors, allowing analyses from pre-disease risk through established disease and progression.
What makes the MOST dataset uniquely valuable according to the FOA?
A major strength is the depth and duration of the data already collected: more than seven years of repeated clinical and musculoskeletal evaluations. The resource combines longitudinal imaging, clinical measures, functional testing, and biospecimens.
What kinds of imaging data are included?
Data resources include repeated knee radiographs and knee MRI imaging, enabling structural (imaging-based) assessments of osteoarthritis over time.
What kinds of functional or performance measures are included?
The study includes strength testing and physical performance measures, enabling functional (performance-based) assessments in addition to imaging and clinical evaluations.
Are biological samples available through the MOST study?
Yes. The cohort includes plasma samples and has an established specimen bank intended to support future biochemical and genetic investigations.
What types of future analyses does the specimen bank support?
The specimen bank is intended to support biochemical and genetic investigations, including studying biomarkers relevant to OA risk, onset, and progression.
What kinds of research questions can this resource support?
Based on the described data types, the resource supports a wide range of questions such as validation of imaging markers, identification of predictors of progression, and exploration of biological pathways through biomarker and genetic analyses.
What is the NIH activity category and CFDA number?
The FOA falls under the NIH health-related activity category and is indexed to CFDA number 93.866 (Aging Research).
Is cost sharing or matching required?
No. The announcement states that cost sharing or matching is not required.
When was this opportunity posted and when did it close?
The opportunity was posted on August 6, 2013. The original and current closing date listed is September 7, 2017. It was archived on October 8, 2017.
Is this funding opportunity still active?
No. It is archived (archived date: October 8, 2017), and the listed closing date is September 7, 2017.
What organizations are listed as eligible to apply?
The eligibility section lists a broad range of applicant organization types commonly included in NIH announcements (for example, public and private institutions of higher education and various nonprofit categories), including designations such as HBCUs, HSIs, TCCUs, and other serving institutions.
Even with broad eligibility language, who is the opportunity really intended for?
Practically, eligibility is effectively constrained by the purpose of the FOA: it is a limited competition intended for the existing MOST investigators to submit the renewal application.
Are non-U.S. (foreign) institutions eligible to apply as applicant organizations?
No. Non-U.S. (foreign) institutions are not eligible to apply as applicant organizations for this opportunity.
Are non-domestic components of U.S. organizations allowed?
Yes. Non-domestic components of U.S. organizations are eligible.
Are foreign components allowed under NIH policy?
Yes. Foreign components (as defined by NIH policy) are allowed.
What is the broader goal of continuing MOST via this U01?
The broader goal described is to sustain rigorous repeated assessments and maximize scientific yield from an established longitudinal cohort and specimen bank to inform prevention strategies, prognostic tools, and biomarker discovery for osteoarthritis.
Browse more opportunities from the same category: Health
Next opportunity: Alcohol Research Resource Awards (R24)
Previous opportunity: National Cancer Institute Program Project Applications (P01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 320
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 320) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alcohol Research Resource Awards (R24) Apply for PAR 13 319 Funding Number: PAR 13 319 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| DNA Sequencing Core for an Undiagnosed Diseases Network (UDN) (U01) Apply for RFA RM 13 018 Funding Number: RFA RM 13 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Health Care Systems Research Collaboratory Demonstration Projects for Pragmatic Clinical Trials Focusing on Multiple Chronic Conditions (UH2/UH3) Apply for RFA RM 13 012 Funding Number: RFA RM 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Urban Indian Health 4 in 1 Program Apply for HHS 2013 IHS UIHP 0002 Funding Number: HHS 2013 IHS UIHP 0002 Agency: Indian Health Service Category: Health Funding Amount: $153,126 |
| Human Cell Reprogramming for Functional Genetics of Alzheimers Disease (R01) Apply for RFA AG 14 012 Funding Number: RFA AG 14 012 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research to Improve the Care of Persons at Clinical High Risk for Psychotic Disorders (Collaborative R01) Apply for RFA MH 14 210 Funding Number: RFA MH 14 210 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research to Improve the Care of Persons at Clinical High Risk for Psychotic Disorders (R01) Apply for RFA MH 14 211 Funding Number: RFA MH 14 211 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research to Improve the Care of Persons at Clinical High Risk for Psychotic Disorders (R34) Apply for RFA MH 14 212 Funding Number: RFA MH 14 212 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| PPHF 2013 Immunization Increasing Human Papillomavirus (HPV) Vaccination Coverage Rates among Adolescents financed solely by 2013 Prevention and Public Health Funds Apply for CDC RFA IP13 130101PPHF13 Funding Number: CDC RFA IP13 130101PPHF13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Methods for Prevention Packages Program III (MP3 III) (R01) Apply for PAR 13 322 Funding Number: PAR 13 322 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| IIS Sentinel Site Pandemic Preparedness and Response Planning Apply for CDC RFA IP13 130201SUPP13 Funding Number: CDC RFA IP13 130201SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| 2014 NIH Pioneer Award Program (DP1) Apply for RFA RM 13 006 Funding Number: RFA RM 13 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| 2014 NIH Directors New Innovator Award Program (DP2) Apply for RFA RM 13 007 Funding Number: RFA RM 13 007 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Limited Pilot for NIGMS Legacy Community Wide Scientific Resources (R24) Apply for PAR 13 324 Funding Number: PAR 13 324 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants for Early Medical/Surgical Specialists Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 14 010 Funding Number: RFA AG 14 010 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| NIA Revision and Resubmission Program Project Applications (P01) Apply for PAR 13 329 Funding Number: PAR 13 329 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Audacious Goals Initiative High Priority Research Area Intersection of Aging and Biological Mechanisms of Eye Disease (R01) Apply for PA 13 332 Funding Number: PA 13 332 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bridges to Baccalaureate Program (R25) Apply for PAR 13 333 Funding Number: PAR 13 333 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| State and Regional Primary Care Association (PCA) Cooperative Agreements for Alaska, Georgia, and Wyoming Apply for HRSA 14 032 Funding Number: HRSA 14 032 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Indian Health Outreach and Education II Apply for HHS 2013 IHS NIHOE 0002 Funding Number: HHS 2013 IHS NIHOE 0002 Agency: Indian Health Service Category: Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 320", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.